88 related articles for article (PubMed ID: 8118224)
1. Serum ferritin in thyroid cancer.
Deshpande UR; Nadkarni GD; Samuel AM
Thyroid; 1993; 3(4):301-3. PubMed ID: 8118224
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers in the diagnosis of thyroid cancer].
Slavnov VN; Markov VV; Kovalenko AE; Kovpan NA; Kvacheniuk AN
Lik Sprava; 1997; (4):31-4. PubMed ID: 9471369
[TBL] [Abstract][Full Text] [Related]
3. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
Westbury C; Vini L; Fisher C; Harmer C
Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Tuttle RM; Fleisher M; Francis GL; Robbins RJ
J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratins determination in differentiated thyroid carcinoma.
Appetecchia M; Meçule A; Ducci M; Palma L; Castelli M
J Exp Clin Cancer Res; 2001 Jun; 20(2):253-6. PubMed ID: 11484983
[TBL] [Abstract][Full Text] [Related]
6. The role of estimation of the ratio of preoperative serum thyroglobulin to the thyroid mass in predicting the behaviour of well differentiated thyroid cancers.
Sharma AK; Sarda AK; Chattopadhyay TK; Kapur MM
J Postgrad Med; 1996; 42(2):39-42. PubMed ID: 9715297
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
8. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.
Lin JD; Huang MJ; Juang JH; Chao TC; Huang BY; Chen KW; Chen JY; Li KL; Chen JF; Ho YS
Thyroid; 1999 Dec; 9(12):1227-35. PubMed ID: 10646663
[TBL] [Abstract][Full Text] [Related]
9. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
10. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
[TBL] [Abstract][Full Text] [Related]
11. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
[TBL] [Abstract][Full Text] [Related]
12. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
14. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
Kołomecki K; Maciaszczyk P; Stepień H; Cywiński J; Cielecka J; Stepień T; Kuzdak K
Endokrynol Pol; 2006; 57(4):320-5. PubMed ID: 17006831
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma.
Suzuki S; Furukawa H; Tsuchiya A
Thyroid; 1999 Sep; 9(9):921-5. PubMed ID: 10524571
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.
Robbins RJ; Srivastava S; Shaha A; Ghossein R; Larson SM; Fleisher M; Tuttle RM
J Clin Endocrinol Metab; 2004 Dec; 89(12):6010-6. PubMed ID: 15579752
[TBL] [Abstract][Full Text] [Related]
18. Serum ferritin: a tumor marker for renal cell carcinoma.
Essen A; Ozen H; Ayhan A; Ergen A; Tasar C; Remzi F
J Urol; 1991 Jun; 145(6):1134-7. PubMed ID: 2033679
[TBL] [Abstract][Full Text] [Related]
19. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of papillary and follicular thyroid carcinoma.
Lin JD; Jeng LB; Chao TC; Weng HF; Huang HS
Int Surg; 1996; 81(1):61-6. PubMed ID: 8803709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]